Caption Management LLC Has $104,000 Stake in The Chemours Company $CC

Key Points

• Caption Management LLC significantly reduced its stake in The Chemours Company by 93.9% in the first quarter, owning only 7,694 shares after selling 117,980 shares.
• CEO Denise Dignam increased her ownership in Chemours by purchasing 4,068 shares at an average of $12.06 per share, raising her total holdings to approximately $2.31 million.
• Analyst ratings for Chemours vary, with a consensus rating of "Moderate Buy" and a target price of $17.38.

Caption Management LLC lowered its stake in The Chemours Company (NYSE:CC - Free Report) by 93.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,694 shares of the specialty chemicals company's stock after selling 117,980 shares during the quarter. Caption Management LLC's holdings in Chemours were worth $104,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. FNY Investment Advisers LLC bought a new position in Chemours during the first quarter worth about $27,000. UMB Bank n.a. grew its holdings in Chemours by 73.9% during the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares during the period. Farther Finance Advisors LLC grew its holdings in Chemours by 170.7% during the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 1,444 shares during the period. SouthState Corp bought a new position in Chemours during the first quarter worth about $34,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Chemours during the fourth quarter worth about $91,000. Institutional investors and hedge funds own 76.26% of the company's stock.

Chemours Stock Performance

Shares of NYSE:CC traded up $0.56 during trading on Friday, reaching $15.65. 4,308,402 shares of the stock were exchanged, compared to its average volume of 3,435,617. The Chemours Company has a 12 month low of $9.13 and a 12 month high of $22.38. The firm has a market cap of $2.34 billion, a PE ratio of -5.59 and a beta of 1.61. The stock has a 50-day moving average price of $13.73 and a 200-day moving average price of $12.78. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.12. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The company had revenue of $1.62 billion during the quarter, compared to analysts' expectations of $1.57 billion. During the same quarter in the previous year, the company posted $0.38 earnings per share. The business's revenue was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts expect that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, August 15th. Chemours's payout ratio is presently -12.50%.

Insider Buying and Selling at Chemours

In other Chemours news, CEO Denise Dignam purchased 4,068 shares of the company's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the transaction, the chief executive officer owned 191,546 shares in the company, valued at approximately $2,310,044.76. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.47% of the company's stock.

Wall Street Analysts Forecast Growth

CC has been the subject of a number of research analyst reports. The Goldman Sachs Group reduced their price target on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Mizuho lifted their price target on Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a report on Tuesday, July 15th. Wall Street Zen cut Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Zacks Research upgraded Chemours from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 27th. Finally, Barclays reduced their price target on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $17.38.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.